Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia
ConclusionPatients with an e13a2 transcript demonstrate an inferior molecular response to imatinib in our regional population.
Source: BMC Hematology - Category: Hematology Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Databases & Libraries | Genetics | Gleevec | Hematology | Laboratory Medicine | Leukemia | Molecular Biology